Abeclib 200 mg (Abemaciclib) – A Targeted Therapy for Advanced Breast Cancer
Abeclib 200 mg, containing the active ingredient Abemaciclib, is a powerful CDK4/6 inhibitor used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. This medication, manufactured by Eskayef Pharmaceuticals Ltd. and distributed globally by Saif Pharma, is a part of the evolving targeted therapies that are reshaping the breast cancer treatment landscape.
What is Abeclib 200 mg (Abemaciclib)?
Abeclib 200 mg is an orally administered kinase inhibitor designed to slow the progression of cancer by interfering with proteins that promote the growth of cancer cells. It targets the cyclin-dependent kinases 4 and 6 (CDK4/6), which are key regulators in cell cycle progression. By inhibiting these enzymes, Abeclib effectively prevents the multiplication of cancer cells, helping to stop or delay tumor growth.
Indications for Use
Abeclib 200 mg is approved for multiple indications and can be used either alone or in combination with other hormone therapies for the treatment of breast cancer. It is specifically indicated for:
Monotherapy
For adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer who have experienced disease progression following endocrine therapy and prior chemotherapy.In Combination with Aromatase Inhibitors
As initial endocrine-based therapy in postmenopausal women and men with HR-positive, HER2-negative advanced or metastatic breast cancer.In Combination with Fulvestrant
For patients with HR-positive, HER2-negative breast cancer whose disease has progressed after endocrine therapy.Adjuvant Therapy
In combination with endocrine therapy (either tamoxifen or an aromatase inhibitor) for the adjuvant treatment of early-stage, node-positive breast cancer at high risk of recurrence, particularly in patients with a Ki-67 score ≥20%.
Mechanism of Action
Abemaciclib, the active compound in Abeclib, selectively inhibits CDK4 and CDK6. These enzymes are critical for the transition of cells from the G1 phase to the S phase of the cell cycle. In HR+ breast cancer, this pathway is often overactive, leading to uncontrolled cellular proliferation. By blocking this transition, Abeclib significantly reduces tumor growth and improves clinical outcomes.
Dosage & Administration
The recommended dose of Abeclib 200 mg may vary depending on the treatment setting (monotherapy or combination therapy) and the patient’s clinical condition. It is generally taken orally twice daily, with or without food. Dosage adjustments may be necessary in cases of toxicity or side effects. Patients should follow their healthcare provider’s guidance for optimal results.
Side Effects and Precautions
As with most targeted cancer therapies, Abeclib 200 mg may cause some side effects. Commonly reported adverse reactions include:
Diarrhea
Fatigue
Neutropenia (low white blood cell count)
Nausea
Infections
Abdominal pain
Decreased appetite
Patients undergoing treatment should have regular blood tests to monitor blood cell counts and liver function. It is crucial to report any unusual symptoms to the healthcare provider immediately.
Who Should Not Use Abeclib?
Abeclib 200 mg should be avoided in individuals with:
Known hypersensitivity to Abemaciclib
Severe hepatic impairment
Active infections without treatment
Pregnant or breastfeeding women (due to potential fetal harm)
Women of childbearing potential should use effective contraception during treatment and for at least three weeks after the last dose.
About the Manufacturer: Eskayef Pharmaceuticals Ltd.
Eskayef Pharmaceuticals Ltd., a part of the Transcom Group, is one of the most respected and quality-focused pharmaceutical manufacturers in Bangladesh. With over three decades of pharmaceutical excellence, Eskayef is renowned for producing world-class oncology and specialty medicines that meet stringent international standards. Their dedication to research, quality, and patient care makes Eskayef a trusted name in the medical community worldwide.
More info: www.skfbd.com
Global Supplier: Saif Pharma
Saif Pharma is a leading supplier of oncology medications, including Abeclib 200 mg, serving patients and healthcare providers across 60+ countries. Since its inception in 2014, Saif Pharma has focused on ensuring affordable, high-quality cancer medicines are accessible globally. With a strong distribution network in the USA, Canada, Saudi Arabia, UAE, India, China, and Pakistan, Saif Pharma stands out for its commitment to patient care and dependable delivery.
Visit us: www.saifpharma.com
Why Choose Abeclib 200 mg from Saif Pharma?
FDA-approved indications
Sourced from a WHO-GMP certified facility (Eskayef Pharmaceuticals)
Competitive pricing for global markets
Worldwide shipping to 60+ countries
Responsive customer support for bulk orders and inquiries
Ordering Information
Abeclib 200 mg (Abemaciclib) is available for bulk purchase, hospital supply, and individual patient use through Saif Pharma’s secure distribution channels. We ensure discreet, fast, and safe delivery with all regulatory compliance maintained.
To order or inquire about Abeclib 200 mg pricing and availability, please contact our team via our official website:
www.saifpharma.com
Frequently Asked Questions (FAQs)
Q1: Is Abeclib 200 mg safe for long-term use?
A: Yes, when monitored correctly by an oncologist, Abeclib has shown efficacy and safety in long-term cancer treatment protocols.
Q2: Can Abeclib be used alone?
A: Yes, it is approved as monotherapy for specific cases. However, it is more commonly used in combination with other hormone therapies.
Q3: What should I do if I miss a dose?
A: Skip the missed dose and take the next one at the usual time. Do not take two doses at once.
Q4: How long does the treatment last?
A: Treatment duration varies based on the patient’s response and tolerance. It can range from several months to years under medical supervision.
Conclusion
Abeclib 200 mg (Abemaciclib) represents a significant advancement in the management of HR+, HER2- advanced breast cancer. Backed by strong clinical data, it offers patients improved progression-free survival and a better quality of life. With manufacturing excellence from Eskayef Pharmaceuticals and global availability via Saif Pharma, Abeclib is a trusted option for oncologists and patients worldwide.
